Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...
$ 81.33 0.23 0.28% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback